Heparin Market Size & Share Analysis - Industry Research Report

Heparin Market Size and Share

Market Overview

Study Period	2019 - 2030
Market Size (2025)	USD 10.04 Billion
Market Size (2030)	USD 14.16 Billion
Growth Rate (2025 - 2030)	7.13% CAGR
Fastest Growing Market	Asia Pacific
Largest Market	Asia Pacific
Market Concentration	Medium
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Heparin Market (2025 - 2030) — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Heparin Market Analysis by Mordor Intelligence

The heparin market size stands at USD 10.04 billion in 2025 and is projected to reach USD 14.16 billion by 2030, reflecting a 7.13% CAGR. Rising surgical volumes, growth in dialysis procedures, and broader applications in oncology care and medical devices keep demand strong. Supply-chain diversification, particularly the move toward biosynthetic production, is emerging as a strategic priority as African Swine Fever–related shortages revealed the risks of heavy porcine dependence. Regulatory support for re-introducing bovine-sourced heparin and funding for bioengineered alternatives further strengthen the outlook. Competitive activity centers on portfolio expansion and geographic reach, while hospitals remain the largest buying segment.

Key Report Takeways

By product type, low-molecular-weight heparin held 63% of heparin market share in 2024, while synthetic/biosynthetic heparin is forecast to grow at 8.40% CAGR to 2030.
By source, porcine material accounted for 87.50% of the heparin market size in 2024; recombinant microbial sources are advancing at 9.10% CAGR through 2030.
By application, deep vein thrombosis led with a 46.20% share of the heparin market size in 2024 and hemodialysis is growing fastest at 7.80% CAGR.
By dosage form, injectable solutions captured 68.40% revenue share in 2024; pre-filled syringes are expanding at a 7.40% CAGR.
By route of administration, subcutaneous delivery represented 54.60% of 2024 revenues, while intravenous delivery progresses at 7.09% CAGR to 2030.
By end user, hospitals commanded 72.30% of 2024 revenue and home-care settings post the highest CAGR at 8.60%.
By region, Asia-Pacific led with a 32.10% share in 2024, and the same region is forecast to expand at 8.19% CAGR through 2030

Global Heparin Market Trends and Insights

Drivers Impact Analysis

Driver	(~) % Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
Escalating surgical procedure volumes and dialysis procedures	+1.7%	Global, with higher impact in North America, Europe, and developed Asia-Pacific regions	Short term (≤ 2 years)
Rapid adoption of low-molecular-weight heparin coupled with expansion of biosynthetic heparin programs	+1.4%	North America, Europe, and developed Asia-Pacific markets	Medium term (2-4 years)
High burden of targeted diseases and ageing population	+1.2%	Global, with pronounced effect in regions with rapidly aging populations (Europe, North America, Japan, China)	Long term (≥ 4 years)
Expanding application in medical devices	+0.8%	North America, Europe, and advanced healthcare markets in Asia-Pacific	Medium term (2-4 years)
Increasing application in oncology care	+0.7%	North America, Europe, and emerging applications in Asia-Pacific	Medium term (2-4 years)
Escalating use of heparin in extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass circuits	+0.5%	Primarily North America and Europe, with growing adoption in advanced Asian healthcare systems	Short term (≤ 2 years)

Source: Mordor Intelligence

Escalating Surgical Procedure Volumes and Dialysis Procedures

Cardiovascular and orthopedic surgeries continue to increase, and both settings rely on prophylactic anticoagulation, keeping heparin demand high. Dialysis sessions are also rising as end-stage renal disease prevalence climbs. Recent trials show that heparin-coated dialyzers plus intermittent saline flushing eliminated clotting events in high-bleeding-risk patients. Regional anticoagulation techniques now allow acid and heparin-free dialysis for select cases, yet overall procedure growth sustains volume through 2027.

Rapid Adoption of Low-Molecular-Weight Heparin and Biosynthetic Programs

Clinicians favor LMWH for its predictable pharmacokinetics and limited monitoring needs, supporting steady share gains. Parallel advances in bioengineered heparin show E. coli-based systems producing material chemically comparable to porcine products and convertible to LMWH^{[1]Marc Douaisi, “Synthesis of Bioengineered Heparin Chemically and Biologically Similar to Porcine-Derived Products,” pnas.org}. In 2025, the NHLBI funded a US USD 306,656 project to scale microbial production, underlining momentum for non-animal sources.

High Disease Burden and Aging Population

Atrial fibrillation affects an estimated 2% of people worldwide and far more among the elderly driving acute heparin therapy in hospital settings. Updated 2024 venous-thromboembolism guidelines introduced 78 new perioperative recommendations, reinforcing routine anticoagulation protocols that favor heparin in many acute scenarios. Coupled with rising life expectancy in Asia-Pacific and Europe, patient pools will widen across the forecast horizon.

Expanding Application in Medical Devices

Device makers increasingly coat vascular grafts and reservoirs with immobilized heparin to improve hemocompatibility. FDA clearance of the GORE PROPATEN vascular graft in March 2024 underscored regulatory confidence in such technology^{[2]W. L. Gore & Associates, “GORE PROPATEN Vascular Graft 510(k) Summary,” fda.gov}. Medtronic’s venous reservoir bag, granted in May 2024, uses non-leaching heparin to reduce clot risk during bypass surgery. Research into heparin-binding silk proteins also suggests antimicrobial plus anticoagulant catheters for dialysis.

Restraints Impact Analysis

Restraint	(~) % Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
Supply-chain vulnerability due to dependence on animal-derived raw material	−1.1%	Global, with severe impact in regions dependent on imports (North America, Europe) and production regions (China)	Short term (≤ 2 years)
Risk and adverse bleeding events	−0.8%	Global, with higher impact in regions with stricter pharmacovigilance (North America, Europe)	Medium term (2-4 years)
Stringent regulatory requirements	−0.7%	North America, Europe, and increasingly in Asia-Pacific markets adopting stricter regulations	Medium term (2-4 years)
Therapeutic shift toward direct oral anticoagulants in long-term thromboprophylaxis	−0.9%	Primarily North America and Europe, with gradual adoption in advanced Asian healthcare markets	Long term (≥ 4 years)

Source: Mordor Intelligence

Supply-Chain Vulnerability due to Animal-Derived Raw Material

About 80% of active pharmaceutical ingredient volumes originate in China, leaving markets exposed to disease outbreaks and geopolitical actions. The 2019-2021 African Swine Fever crisis tightened supplies and lifted costs. In 2025, the FDA encouraged bovine-sourced heparin to diversify supply, citing improved purification that removes BSE prions.

Risk and Adverse Bleeding Events

Heparin-induced thrombocytopenia affects up to 5% of treated patients and can result in serious complications. Comparative studies show bovine and porcine variants trigger similar platelet aggregation in HIT antibodies^{[3]Gia Kapur, “Induced Platelet Aggregation in Porcine and Bovine Heparin,” angiology.org}. Direct oral anticoagulants offer alternative therapy and feature in 2025 hematology guidelines, putting pressure on traditional heparin use.

Segment Analysis

By Product: LMWH Leads, Biosynthetic Gains

Low-molecular-weight heparin held 63% of revenues in 2024, supported by once-daily dosing that suits outpatient use. The heparin market reports consistent switching from unfractionated heparin to LMWH in surgical prophylaxis and oncology settings. The segment’s steady volume has prompted manufacturers to expand syringe formats for safer bedside administration.

Synthetic and biosynthetic heparin is the fastest-growing product line at 8.40% CAGR, reflecting investment in microbial and chemo-enzymatic pathways that bypass porcine inputs. As these alternatives reach scale, they may reshape overall heparin market share by the decade’s end.

Market Segment Share — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Source: Porcine Dominates, Microbial Ascends

Porcine mucosa supplied 87.50% of global volume in 2024, anchoring production hubs in China’s coastal provinces. The heparin market size for porcine source is sensitive to herd-health shocks and tariffs that raise cost for importing countries. Recombinant microbial sources, growing at 9.10% CAGR, attract private capital and public grants aimed at supply-chain resilience.

Bovine material is returning to regulated markets after updated FDA guidance demonstrated that modern purification removes BSE agents. Early adopters aim to smooth volatility in porcine supply while maintaining pharmacologic equivalence.

By Dosage Form: Injectable Solutions Prevail

Injectable solutions commanded 68.40% of 2024 sales, confirming continued reliance on parenteral delivery for inpatient therapies. Pre-filled syringes rank as the fastest adopter at 7.40% CAGR, helped by simplified handling and lower contamination risk. Fresenius Kabi’s Simplist syringes underline how packaging innovation drives both safety and uptake.

Topical gels serve niche indications but benefit from over-the-counter visibility in Europe and Asia. Heparin-coated devices and depot formulations remain in pilot stages, yet they expand the dosage-form spectrum that underpins future heparin market growth.

By Route of Administration: Subcutaneous Rules

Subcutaneous delivery contributed 54.60% of 2024 volume as LMWH dominates prophylactic regimens outside the hospital. Patient self-administration supports shorter hospital stays, aligning with cost-containment goals. Intravenous delivery is essential for acute interventions and is projected at a 7.09% CAGR, thanks to procedural demand in cardiology and cardiac surgery.

Administration protocols are adapting to new ablation techniques and extracorporeal life support, ensuring both routes remain integral to the long-term heparin market.

By Application: DVT Prevention Dominates

Deep vein thrombosis accounted for 46.20% of 2024 revenues, anchored by guideline-mandated prophylaxis after major orthopedic and abdominal surgeries. Hemodialysis usage is rising at 7.80% CAGR as global renal-failure prevalence intensifies. New dialyzer coatings reduce systemic anticoagulation yet retain heparin as the cornerstone for circuit patency.

Atrial fibrillation procedures and acute coronary syndromes round out high-volume indications, keeping the heparin market diversified across clinical specialties.

By End User: Hospitals Dominate, Home Care Expands

Hospitals absorbed 72.30% of heparin purchases in 2024, where intensive monitoring and rapid dose titration remain critical. Yet home-care adoption, growing at 8.60% CAGR, benefits from user-friendly syringes and telehealth follow-up. Ambulatory centers and specialty clinics deepen penetration in oncology, cardiology, and nephrology, broadening distribution channels.

Geography Analysis

North America recorded sizable demand in 2024, driven by high surgical procedure volumes and chronic dialysis populations. FDA encouragement for bovine sourcing seeks to stabilize supplies while tariffs on Chinese imports highlight procurement risks. Classification of new heparin test systems into Class II special controls exemplifies the tightening regulatory climate.

Asia-Pacific delivered 32.10% of global revenue and posted the fastest CAGR at 8.19%. China’s processing base remains indispensable, though recent policy reviews urge stronger R&D and quality oversight to ensure enduring competitiveness. Emerging self-sufficiency programs in India and Southeast Asia aim to localize API production, potentially expanding regional heparin market supply.

Europe maintains a stable share as aging demographics and well-funded health systems support steady consumption. EMA conformity assessments for device-drug combinations enforce rigorous safety standards ema.europa.eu. Biosimilar pathways differ from US practice, influencing launch timelines and competitive intensity among low-molecular-weight brands.

Geography growth — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The heparin market features moderate consolidation, with Pfizer, Baxter International, and Sanofi anchoring global supply and maintaining broad therapeutic portfolios. Asian specialists including Hebei Changshan and Shenzhen Hepalink scale exports to capture incremental share. Strategic moves revolve around localizing manufacturing, forming supply agreements, and launching pre-filled delivery systems.

Supply-chain resilience is a pivotal competitive factor. Companies are evaluating dual sourcing, increased inventory buffers, and in-house bioengineering platforms to hedge porcine volatility. BIOPARIN’s US grant funding underscores growing institutional support for microbial pathways that promise controlled quality and geographic flexibility.

Regulatory shifts further shape rivalry. FDA support for bovine sourcing opens space for new entrants versed in ruminant purification, while EMA’s differentiated biosimilar requirements may slow follow-on approval compared with the US. Coupled with heightened oversight after past contamination events, firms that demonstrate traceability and analytical control can gain lasting advantage.

Heparin Industry Leaders

Opocrin SpA
Baxter International
B Braun Melsungen AG
Pfizer Inc.
Sanofi
*Disclaimer: Major Players sorted in no particular order

Heparin Market Concentration — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Need More Details on Market Players and Competitors?

Download PDF

Recent Industry Developments

February 2025: BIOPARIN secures a USD 306,000 NHLBI STTR grant to scale bio-manufacturing of microbial heparin.
January 2025: FDA guidance encourages re-introduction of bovine-sourced heparin, signaling policy support for diversified raw materials
August 2024: Baxter recalls a lot of heparin sodium due to elevated endotoxin levels; no adverse events reported.
May 2024: Medtronic gains FDA clearance for venous reservoir bag with non-leaching heparin coating.

Table of Contents for Heparin Industry Report

1. Introduction

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

4.1 Market Overview
4.2 Market Drivers
- 4.2.1 Escalating Surgical Procedure Volumes and Dialysis Procedures
- 4.2.2 Rapid Adoption of Low-Molecular-Weight Heparin Coupled with Expansion of Biosynthetic Heparin Programs
- 4.2.3 High Burden of Targeted Diseases and Ageing Population
- 4.2.4 Expanding Application in Medical Devices
- 4.2.5 Increasing Application in Oncology Care
- 4.2.6 Escalating Use of Heparin in Extracorporeal Membrane Oxygenation (ECMO) and Cardiopulmonary Bypass Circuits
4.3 Market Restraints
- 4.3.1 Supply-Chain Vulnerability due to Dependence on Animal Derived Raw Material
- 4.3.2 Risk and Adverse Bleeding Events
- 4.3.3 Stringent Regulatory Requirements
- 4.3.4 Therapeutic Shift Toward Direct Oral Anticoagulants in Long-term Thromboprophylaxis
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Outlook
4.6 Technological Outlook
4.7 Porter's Five Forces
- 4.7.1 Threat of New Entrants
- 4.7.2 Bargaining Power of Buyers
- 4.7.3 Bargaining Power of Suppliers
- 4.7.4 Threat of Substitute Products
- 4.7.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts (Value in USD)

5.1 By Product
- 5.1.1 Unfractionated Heparin
- 5.1.2 Low-Molecular-Weight Heparin (LMWH)
- 5.1.3 Ultra-Low-Molecular-Weight Heparin (ULMWH)
- 5.1.4 Synthetic / Biosynthetic Heparin
5.2 By Source
- 5.2.1 Porcine
- 5.2.2 Bovine
- 5.2.3 Recombinant Microbial
5.3 By Dosage Form
- 5.3.1 Injectable Solution
- 5.3.1.1 Injectable Solution, Pre-filled Syringe, Topical Gel / Cream and Others
- 5.3.2 Pre-filled Syringe
- 5.3.3 Topical Gel / Cream
- 5.3.4 Others
5.4 By Route of Administration
- 5.4.1 Intravenous
- 5.4.2 Sub-cutaneous
5.5 By Application
- 5.5.1 Deep Vein Thrombosis (DVT)
- 5.5.2 Atrial Fibrillation and Heart Attack
- 5.5.3 Coronary Artery Disease
- 5.5.4 Hemodialysis
- 5.5.5 Other Applications
5.6 By End User
- 5.6.1 Hospitals
- 5.6.2 Ambulatory Surgical Centers
- 5.6.3 Specialty Clinics
- 5.6.4 Home-care Settings
5.7 Geography
- 5.7.1 North America
- 5.7.1.1 United States
- 5.7.1.2 Canada
- 5.7.1.3 Mexico
- 5.7.2 Europe
- 5.7.2.1 Germany
- 5.7.2.2 United Kingdom
- 5.7.2.3 France
- 5.7.2.4 Italy
- 5.7.2.5 Spain
- 5.7.2.6 Rest of Europe
- 5.7.3 Asia-Pacific
- 5.7.3.1 China
- 5.7.3.2 Japan
- 5.7.3.3 India
- 5.7.3.4 South Korea
- 5.7.3.5 Australia
- 5.7.3.6 Rest of Asia-Pacific
- 5.7.4 Middle East and Africa
- 5.7.4.1 GCC
- 5.7.4.2 South Africa
- 5.7.4.3 Rest of Middle East and Africa
- 5.7.5 South America
- 5.7.5.1 Brazil
- 5.7.5.2 Argentina
- 5.7.5.3 Rest of South America

6. Competitive Landscape

6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
- 6.4.1 B. Braun Melsungen AG
- 6.4.2 Baxter International Inc.
- 6.4.3 Dr. Reddy's Laboratories Ltd.
- 6.4.4 Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
- 6.4.5 Leo Pharma A/S
- 6.4.6 Opocrin S.p.A.
- 6.4.7 Pfizer Inc.
- 6.4.8 Fresenius Kabi AG
- 6.4.9 Gland Pharma Ltd.
- 6.4.10 Hikma Pharmaceuticals PLC
- 6.4.11 Techdow Pharma USA Inc.
- 6.4.12 Viatris Inc.
- 6.4.13 Abbott
- 6.4.14 Smiths Medical (ICU Medical)
- 6.4.15 Sanofi S.A.
- 6.4.16 Shenzhen Hepalink Pharmaceutical Co. Ltd.
- 6.4.17 Bioiberica S.A.U.
- 6.4.18 Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd.
- 6.4.19 Cipla
- 6.4.20 Emcure Pharmaceuticals Ltd

7. Market Opportunities and Future Outlook

7.1 White-space and Unmet-Need Assessment

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections

Get Price Break-up Now

Global Heparin Market Report Scope

As per the scope of the report, heparin is used as an anticoagulation agent that allows the body's natural clot lysis mechanisms to work normally to break down clots that have formed. The heparin market is segmented by product (unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH), source (bovine and porcine), application (deep vein thrombosis (DVT), atrial fibrillation and heart attack, coronary artery disease, and other applications), and by geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The market report also covers the estimated market sizes and trends for 17 different countries across the major regions globally. The report offers the value (in USD million) for all the above segments.

By Product	Unfractionated Heparin
	Low-Molecular-Weight Heparin (LMWH)
	Ultra-Low-Molecular-Weight Heparin (ULMWH)
	Synthetic / Biosynthetic Heparin
By Source	Porcine
	Bovine
	Recombinant Microbial

By Dosage Form	Injectable Solution	Injectable Solution, Pre-filled Syringe, Topical Gel / Cream and Others
	Pre-filled Syringe
	Topical Gel / Cream
	Others
By Route of Administration	Intravenous
	Sub-cutaneous
By Application	Deep Vein Thrombosis (DVT)
	Atrial Fibrillation and Heart Attack
	Coronary Artery Disease
	Hemodialysis
	Other Applications
By End User	Hospitals
	Ambulatory Surgical Centers
	Specialty Clinics
	Home-care Settings

Geography	North America	United States
		Canada
		Mexico

	Europe	Germany
		United Kingdom
		France
		Italy
		Spain
		Rest of Europe

	Asia-Pacific	China
		Japan
		India
		South Korea
		Australia
		Rest of Asia-Pacific

	Middle East and Africa	GCC
		South Africa
		Rest of Middle East and Africa

	South America	Brazil
		Argentina
		Rest of South America

By Product

Unfractionated Heparin

Low-Molecular-Weight Heparin (LMWH)

Ultra-Low-Molecular-Weight Heparin (ULMWH)

Synthetic / Biosynthetic Heparin

By Source

Porcine

Bovine

Recombinant Microbial

By Dosage Form

Injectable Solution	Injectable Solution, Pre-filled Syringe, Topical Gel / Cream and Others
Pre-filled Syringe
Topical Gel / Cream
Others

By Route of Administration

Intravenous

Sub-cutaneous

By Application

Deep Vein Thrombosis (DVT)

Atrial Fibrillation and Heart Attack

Coronary Artery Disease

Hemodialysis

Other Applications

By End User

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

Home-care Settings

Geography

North America	United States
	Canada
	Mexico
Europe	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe
Asia-Pacific	China
	Japan
	India
	South Korea
	Australia
	Rest of Asia-Pacific
Middle East and Africa	GCC
	South Africa
	Rest of Middle East and Africa
South America	Brazil
	Argentina
	Rest of South America